Onvatilimab
Based on 1 publication(s) in Google Scholar
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research.
For research use only. We do not sell to patients.
- Purity: 98.00%
- CAS No.: 1969313-51-6
- Molecular Weight:144.52 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Onvatilimab
More
Biological Activity
Human IgG1 kappa
Human
B7-H5/VISTA
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded VISTA/B7-H5 Protein, Human (HEK293, Fc, HY-P77879) on SA biosensor, can bind Onvatilimab with an affinity constant of 2.039E-10 M as determined in BLI assay. -
Flow cytometric analysis of 106 Jurkat cells labeling Onvatilimab (HY-P99040, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1969313-51-6
-
Appearance Liquid
-
Molecular Weight 144.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Onvatilimab]
-
Synonyms
JNJ-61610588; CI-8993; VSTB112
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma. [Abstract]2026 Jan 22:S1535-6108(25)00554-9. PMID: 41576930
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Katsiaryna Marhelava, et al. Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers (Basel). 2019 Nov 8;11(11):1756. [Content Brief]
[2]. Wu L, et al. METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer. J Immunother Cancer. 2024 Dec 9;12(12):e009865. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)